{"symbol":"REGN","fiscalQuarter":"Q4-2009","reportDate":"2010-02-18","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q4-2009","postBrief":{"headline":"Regeneron Pharmaceuticals Misses on EPS \u2014 Stock Down 12.48%","keyNumbers":[{"metric":"EPS","actual":"$-0.46","expected":"N/A","surprise":"-35.69%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Defensive","keyQuotes":["Management expressed concerns over recent performance.","They highlighted challenges in the current market environment.","No specific guidance was provided for the upcoming quarters."],"summary":"Overall, management acknowledged the difficulties faced during the quarter. They did not provide any forward guidance, indicating uncertainty about future performance."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's earnings report indicates a challenging quarter, particularly with a significant EPS miss. The stock reacted negatively, dropping 12.48%, likely due to investor concerns over the company's performance and lack of guidance. The absence of revenue figures further adds to the uncertainty surrounding the company's outlook.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q4 2009 earnings: EPS missed. Stock down 12.48%. Full breakdown."}}